The prostate cancer dilemma : selecting patients for active surveillance, focal ablation and definitive therapy /

Saved in:
Bibliographic Details
Imprint:Cham : Springer, 2016.
Description:1 online resource
Language:English
Subject:
Format: E-Resource Book
URL for this record:http://pi.lib.uchicago.edu/1001/cat/bib/11249025
Hidden Bibliographic Details
Other authors / contributors:Stone, Nelson N., editor.
Crawford, E. David, editor.
ISBN:9783319214856
3319214853
9783319214849
3319214845
Digital file characteristics:text file
PDF
Notes:Includes bibliographical references and index.
Online resource; title from PDF title page (EBSCO, viewed October 29, 2015).
Summary:This comprehensive text provides a complete description of the newest technologies to diagnose and manage the most common prostate cancer diagnosed today: low risk disease. The book reviews new data about genetic markers, transperineal mapping biopsy and mpMRI, how to apply each of these technologies in patients with elevated PSA, when a prior prostate biopsy performed by the standard TRUS method is negative, and, in cases where low risk disease is already diagnosed, how to differentiate those men who might harbor more aggressive disease from those who do not. Over 75% of newly diagnosed prostate cancer meets the criteria for low risk disease which has created a dilemma for both patients and clinicians because of the inaccuracy of the standard TRUS biopsy method. Active surveillance programs have been initiated and are reviewed. How the new technologies impact surveillance programs are addressed. Clinical stage designation is updated and a new intra-prostatic staging system is discussed. Prostate biopsy techniques utilizing transrectal ultrasound, transperineal mapping, elastography and mpMRI are compared. Finally, utilization of these new technologies in the application of focal therapy is reviewed. The Prostate Cancer Dilemma will serve as a valuable resource for clinicians, surgeons and researchers with an interest in early prostate cancer. Chapters are written by experts in their fields and include the most up-to-date scientific and clinical information as well as links to procedural video content.
Other form:Print version: Prostate cancer dilemma. Cham : Springer, 2016 3319214845 9783319214849
Standard no.:10.1007/978-3-319-21485-6

MARC

LEADER 00000cam a2200000Ii 4500
001 11249025
006 m o d
007 cr cnu---unuuu
008 151021s2016 sz ob 001 0 eng d
005 20240710202625.2
016 7 |a 019128723  |2 Uk 
019 |a 926818727  |a 936280928  |a 985049302  |a 1005756732  |a 1012078205  |a 1026449055  |a 1048132988  |a 1066664353  |a 1086462912  |a 1111074266  |a 1112596498  |a 1117224525  |a 1122815839  |a 1162755378 
020 |a 9783319214856  |q (electronic bk.) 
020 |a 3319214853  |q (electronic bk.) 
020 |z 9783319214849 
020 |z 3319214845 
024 7 |a 10.1007/978-3-319-21485-6  |2 doi 
035 |a (OCoLC)925777395  |z (OCoLC)926818727  |z (OCoLC)936280928  |z (OCoLC)985049302  |z (OCoLC)1005756732  |z (OCoLC)1012078205  |z (OCoLC)1026449055  |z (OCoLC)1048132988  |z (OCoLC)1066664353  |z (OCoLC)1086462912  |z (OCoLC)1111074266  |z (OCoLC)1112596498  |z (OCoLC)1117224525  |z (OCoLC)1122815839  |z (OCoLC)1162755378 
035 9 |a (OCLCCM-CC)925777395 
037 |a com.springer.onix.9783319214856  |b Springer Nature 
040 |a N$T  |b eng  |e rda  |e pn  |c N$T  |d IDEBK  |d N$T  |d OCLCQ  |d YDXCP  |d OCLCO  |d CDX  |d OCLCF  |d OCLCO  |d AZU  |d COO  |d GW5XE  |d EBLCP  |d OCLCO  |d KSU  |d IAD  |d JBG  |d ICW  |d VT2  |d Z5A  |d ILO  |d ICN  |d OCLCQ  |d ESU  |d IOG  |d U3W  |d REB  |d WYU  |d OCLCO  |d OCLCA  |d MERER  |d OCLCO  |d UKMGB  |d OCLCQ  |d OCLCO  |d AUD  |d OCLCQ  |d OCLCO  |d DCT  |d ERF  |d LEATE  |d OCLCQ  |d OCLCA  |d AJS  |d OCLCQ  |d OCLCO 
049 |a MAIN 
050 4 |a RC280.P7 
060 4 |a WJ 762 
072 7 |a HEA  |x 039000  |2 bisacsh 
072 7 |a MED  |x 014000  |2 bisacsh 
072 7 |a MED  |x 022000  |2 bisacsh 
072 7 |a MED  |x 112000  |2 bisacsh 
072 7 |a MED  |x 045000  |2 bisacsh 
072 7 |a MJS  |2 bicssc 
245 0 4 |a The prostate cancer dilemma :  |b selecting patients for active surveillance, focal ablation and definitive therapy /  |c Nelson N. Stone, E. David Crawford, editors. 
264 1 |a Cham :  |b Springer,  |c 2016. 
300 |a 1 online resource 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file 
347 |b PDF 
588 0 |a Online resource; title from PDF title page (EBSCO, viewed October 29, 2015). 
504 |a Includes bibliographical references and index. 
505 0 |a Part One: Diagnosis -- History of PSA, from Detection to Over Diagnosis -- Pathology of Prostate Cancer: What has Changed in the Last 30 years?- Clinical Risk Prediction Tools for Prostate Cancer: TMN to CAPRA-Should Risk be Re-defined?- TRUS Biopsy: Is There Still a Role?- Transperineal Biopsy Technique -- 3D Biopsy: A New Method to Diagnose Prostate Cancer -- Elastography: Can it Improve Prostate Biopsy Results?- Multi parametric MRI of the Prostate as a Tool for Prostate Cancer Detection -- Genomic Markers -- Part Two: Treatment -- Current Status of Clinical Trials in Active Surveillance -- Focused targeted Therapy in Prostate Cancer -- Technologies and Methods in Primary Ablation with Focal Therapy -- Multi parametric MRI (mpMRI)-Guided Focal Therapy -- Conclusions. 
520 |a This comprehensive text provides a complete description of the newest technologies to diagnose and manage the most common prostate cancer diagnosed today: low risk disease. The book reviews new data about genetic markers, transperineal mapping biopsy and mpMRI, how to apply each of these technologies in patients with elevated PSA, when a prior prostate biopsy performed by the standard TRUS method is negative, and, in cases where low risk disease is already diagnosed, how to differentiate those men who might harbor more aggressive disease from those who do not. Over 75% of newly diagnosed prostate cancer meets the criteria for low risk disease which has created a dilemma for both patients and clinicians because of the inaccuracy of the standard TRUS biopsy method. Active surveillance programs have been initiated and are reviewed. How the new technologies impact surveillance programs are addressed. Clinical stage designation is updated and a new intra-prostatic staging system is discussed. Prostate biopsy techniques utilizing transrectal ultrasound, transperineal mapping, elastography and mpMRI are compared. Finally, utilization of these new technologies in the application of focal therapy is reviewed. The Prostate Cancer Dilemma will serve as a valuable resource for clinicians, surgeons and researchers with an interest in early prostate cancer. Chapters are written by experts in their fields and include the most up-to-date scientific and clinical information as well as links to procedural video content. 
650 0 |a Prostate  |x Cancer.  |0 http://id.loc.gov/authorities/subjects/sh85107606 
650 0 |a Prostate  |x Cancer  |x Diagnosis. 
650 0 |a Prostate  |x Cancer  |x Treatment. 
650 2 |a Prostatic Neoplasms. 
650 7 |a Oncology.  |2 bicssc 
650 7 |a Pathology.  |2 bicssc 
650 7 |a Urology & urogenital medicine.  |2 bicssc 
650 7 |a HEALTH & FITNESS  |x Diseases  |x General.  |2 bisacsh 
650 7 |a MEDICAL  |x Clinical Medicine.  |2 bisacsh 
650 7 |a MEDICAL  |x Diseases.  |2 bisacsh 
650 7 |a MEDICAL  |x Evidence-Based Medicine.  |2 bisacsh 
650 7 |a MEDICAL  |x Internal Medicine.  |2 bisacsh 
650 7 |a Prostate  |x Cancer.  |2 fast  |0 (OCoLC)fst01079479 
650 7 |a Prostate  |x Cancer  |x Diagnosis.  |2 fast  |0 (OCoLC)fst01079483 
650 7 |a Prostate  |x Cancer  |x Treatment.  |2 fast  |0 (OCoLC)fst01079496 
655 4 |a Electronic books. 
700 1 |a Stone, Nelson N.,  |e editor. 
700 1 |a Crawford, E. David,  |e editor.  |0 http://id.loc.gov/authorities/names/n82022798 
776 0 8 |i Print version:  |t Prostate cancer dilemma.  |d Cham : Springer, 2016  |z 3319214845  |z 9783319214849  |w (OCoLC)911210607 
903 |a HeVa 
929 |a oclccm 
999 f f |i f350928b-43c0-5e31-90af-94aa36139aca  |s 0841d88d-64e1-5ee6-ba47-f4b2a62dd09c 
928 |t Library of Congress classification  |a RC280.P7  |l Online  |c UC-FullText  |u https://link.springer.com/10.1007/978-3-319-21485-6  |z Springer Nature  |g ebooks  |i 12532929